EXPLORE!

TNF-α blockade may lead to improvement of vascular function in psoriasis patients

  878 Views

eMediNexus    17 September 2021

Psoriasis is among the most common chronic inflammatory skin disorder, and suggests a risk factor for cardiovascular disease. The interleukin-17A (IL-17A)-mediated inflammation in psoriasis has been implicated as the contributor to vascular dysfunction. 

A new study published in Experimental Dermatology study investigated if anti-inflammatory treatment by tumor necrosis factor (TNF)-α blockade alters vascular function in psoriasis patients. 

This study recruited 11 patients with psoriasis – who underwent treatment with either adalimumab or etanercept, as well as 10 healthy control individuals and 14 patients with coronary artery disease (CAD).

The results revealed that flow-mediated dilation (FMD) was slightly impaired in psoriasis patients than in the healthy controls. However, anti-TNF-α treatment did not significantly change the FMD levels. Psoriasis patients showed higher baseline vascular activity than healthy controls. Anti-TNF-α treatment significantly improved low-flow-mediated constriction (l-FMC) in psoriasis patients. While FMD and l-FMC in psoriasis patients were comparable to those with CAD. 

Thus, it was concluded that anti-inflammatory treatment with TNF-α blockade improves vascular function in psoriasis patients, mainly by altering the baseline vascular tone. 

Source: Experimental Dermatology. 2021. doi: 10.1111/exd.14452

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.